Full Fed. Circ. Asked To Skip 'Blocking Patent' Case
Generics makers Roxane and Teva urged the full Federal Circuit Tuesday not to rehear a decision invalidating four Acorda patents on the multiple sclerosis drug Ampyra, arguing that the ruling was...To view the full article, register now.
Already a subscriber? Click here to view full article